key: cord-0692788-0ja9j4wd authors: Thangaraj, Jeromie Wesley Vivian; Kumar, Muthusamy Santhosh; Kumar, CP Girish; Kumar, V Saravana; Kumar, Nathella Pavan; Bhatnagar, Tarun; Ponnaiah, Manickam; Sabarinathan, R; Sudharani, D; Nancy, Arul; Jagadeesan, M; Babu, Subash; Murhekar, Manoj title: Persistence of humoral immune response to SARS-CoV-2 up to 7 months post-infection: Cross-sectional study, South India, 2020-21 date: 2021-05-28 journal: J Infect DOI: 10.1016/j.jinf.2021.05.026 sha: 067340928df7df0ff5e7943066f8d5884ec2187b doc_id: 692788 cord_uid: 0ja9j4wd nan This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. Persistence of humoral immune response to SARS-CoV-2 up to 7 months postinfection: Cross-sectional study, South India, 2020-21 Hanrath and colleagues, reported in this Journal that the prior SARS-CoV-2 infection is associated with protection against symptomatic reinfection 1 . Authors suggested further studies to know the durability of protection. SARS-CoV-2 elicits rapid immune response, with seroconversion occurring in majority cases by 10 days post-symptom onset [2] [3] [4] [5] . We enrolled 755 individuals in the study (minimum 100 participants in each time-group). The mean age of the study participants was 41.8 (SD: 12.5) years, and 58.3% (n=440) were males. 81 (10.7%) individuals reported that they were asymptomatic, 44 (5.8%) had severe illness (admitted in ICU or required supplemental oxygen while hospitalization) and 630 (83.4%) were categorized into mild to moderate illness category. Majority were either isolated in COVID care centres (33.1%) or in their homes (37%) and 194 (25.7%) were directly admitted to a hospital or medical institution. 280 (37.1%) reported a chronic comorbidity; the most common being diabetes mellitus (n=176, 23.3%) and hypertension (n=155, 20.5%) ( (Fig-1, Supplementary Table-1) . Sero-positivity to S1-RBD was higher compared to that of NC protein at all time-windows except during the first-time-window of 15-30 days. The proportion of COVID-19 patients sero-positive to NC or S1-RBD declined over time, with respectively 43 (37.1%) and 73 (62.9%) of the 116 patients having antibodies against NC and S1-RBD 180 days respectively, after RT-PCR diagnosis (Supplementary Seropositivity for IgG against NC, S1-RBD and NAbs observed during 15-30-day time period was higher among individuals with severe illness compared to those with a mild/moderate or asymptomatic illness. This pattern was observed during each of the time-window. In particular, IgG seropositivity against NC and S1-RBD protein during the time-window of 151-232 days was 37.5% and 50.0% among individuals with asymptomatic COVID-19 and 43.9% and 63.6% respectively among mild/moderate patients. However, individuals who had a severe illness had higher levels of IgG NC (60%) and S1-RBD (80%) during the same time-window. Similarly, percentage of NAbs among individuals with severe illness (90.0%) was higher compared to who had a mild/moderate (81.3%) or asymptomatic (70.8%). (Supplementary Table-2) . Seropositivity for IgG against NC, S1-RBD and NAbs was not different among males and females during all time-windows (Supplementary table-3) . Seropositivity for NAbs was not different among those with and without comorbidity during all time-windows. Although individuals with comorbidity had higher seropositivity for IgG against NC and S1-RBD during each time-windows, proportion seropositives for these antibodies were not significantly different among those with and without comorbidity (Supplementary table-4) . The decline of anti-NC and anti S1-RBD has an implication on the serosurveys conducted to estimate the proportion of population previously infected with SARS-CoV-2. Most serosurveys use NC or spike assays to estimate seropositivity 2 . Since the pandemic is continuing for more than a year, serosurveys using only one assay would grossly underestimate the seroprevalence. Hence a standard algorithm to use laboratory assays for serosurvey needs to be developed to account for the waning of antibodies. The IgG anti-NC, anti S1-RBD and neutralising antibody waned faster among the individuals with no to mild/moderate symptoms than individuals who had severe illness. Antibody response was more pronounced and long-lasting in individual who had severe disease as documented in other studies 6, 10, 11 . Lower antibody response and relatively faster waning among asymptomatic and individuals with mild/moderate symptoms might be because of strong innate immunity and T cell response in these individuals 2 . Our study has certain limitations. We used cross-sectional design to measure humoral response to SARS-CoV-2 over time whereas cohort design involving longitudinal measurement may be ideal for this purpose. Nevertheless, our cross-sectional estimates provide quick snapshot of immune response and thus may be useful for public health response. We could not compare antibody response over time by age groups (Supplementary table-5) since majority of our study population were in working age group than children and older adults. As a secondary objective, we examined host immune response by clinical severity based on self-reported symptoms, this could have led to misclassification specifically between those reporting asymptomatic status versus mild/moderate symptoms. However, we could validate the severity status from hospitalization records for those categorized as having severe illness. In conclusion, findings of our study indicated that IgG antibodies against NC and S1-RBD Prior SARS-CoV-2 infection is associated with protection against symptomatic reinfection Adaptive immunity to SARS-CoV-2 and COVID-19 Robust neutralizing antibodies to SARS-CoV-2 infection persist for months Antibody responses to SARS-CoV-2 in patients with COVID-19 Orthogonal SARS-CoV-2 Serological Assays Enable Surveillance of Low-Prevalence Communities and Reveal Durable Humoral Immunity Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses EUA authorized serology test performance 2020 Convergent antibody responses to SARS-CoV-2 in convalescent individuals Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology This study was funded by Greater Chennai Corporation, public health department for conducting this survey. We acknowledge the support from Greater Chennai Corporation health officials in field operations.